Therapeutic siRNA for drug-resistant HER2-positive breast cancer

HER2 is overexpressed in about 20% of breast cancers and contributes to poor prognosis. Unfortunately, a large fraction of patients have primary or acquired resistance to the HER2-targeted therapy trastuzumab, thus a multi-drug combination is utilized in the clinic, putting significant burden on pat...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Gu, Shenda, Hu, Zhi, Ngamcherdtrakul, Worapol, Castro, David J., Morry, Jingga, Reda, Moataz M., Gray, Joe W., Yantasee, Wassana
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2016
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4924747/
https://ncbi.nlm.nih.gov/pubmed/26894975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7409
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы